Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (Ux143) in Osteogenesis Imperfecta
Ultragenyx公司因Setrusumab(Ux143)在成骨不全中獲得突破性療法認定。
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (Ux143) in Osteogenesis Imperfecta
Ultragenyx公司因Setrusumab(Ux143)在成骨不全中獲得突破性療法認定。
譯文內容由第三人軟體翻譯。